{"id":3106,"date":"2024-06-25T11:36:44","date_gmt":"2024-06-25T09:36:44","guid":{"rendered":"https:\/\/hmi-test.ezenit.link\/?p=3106"},"modified":"2024-06-25T17:04:06","modified_gmt":"2024-06-25T15:04:06","slug":"hm-hospitales-signs-an-agreement-with-myocardial-solutions-to-assess-the-cardiotoxicity-of-chemotherapy-and-cardiac-function-in-cancer-patient","status":"publish","type":"post","link":"https:\/\/hmi-test.ezenit.link\/en\/hm-hospitales-signs-an-agreement-with-myocardial-solutions-to-assess-the-cardiotoxicity-of-chemotherapy-and-cardiac-function-in-cancer-patient\/","title":{"rendered":"HM Hospitales signs an agreement with Myocardial Solutions to assess the cardiotoxicity of chemotherapy and cardiac function in cancer patient"},"content":{"rendered":"<style>.elementor-3106 .elementor-element.elementor-element-18a0a59{--display:flex;}.elementor-widget-text-editor{font-family:var( --e-global-typography-text-font-family ), Sans-serif;font-weight:var( --e-global-typography-text-font-weight );color:var( --e-global-color-text );}.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:var( --e-global-color-primary );}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap, .elementor-widget-text-editor.elementor-drop-cap-view-default .elementor-drop-cap{color:var( --e-global-color-primary );border-color:var( --e-global-color-primary );}<\/style>\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"3106\" class=\"elementor elementor-3106\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-18a0a59 e-flex e-con-boxed e-con e-parent\" data-id=\"18a0a59\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7a9da414 elementor-widget elementor-widget-text-editor\" data-id=\"7a9da414\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>\u2022 HM Sanchinarro, through HM CIEC and HM CIOCC, becomes the first private\u00a0hospital in Spain to address cardio oncology through the implementation of the\u00a0MyoStrain AI program.<\/strong><\/p><p><strong>\u2022 This is one of the first actions that represent HM Hospitales&#8217; commitment to address Cardiology and Oncology in a multidisciplinary manner, two of the areas of\u00a0greatest interest and specialization of the Group, and the main reasons for mortality\u00a0in 21st century society.<\/strong><\/p><p><strong>\u2022 Through AI Myostrain, a non-invasive evaluation of the cardiac function of the\u00a0cancer patient is achieved before, during and after receiving chemotherapy, indicating the impact on the myocardial tissue, even before symptoms appear.<\/strong><\/p><p>HM Hospitales and Myocardial Solutions have reached a collaboration agreement that\u00a0makes the HM Sanchinarro University Hospital the first private healthcare center in\u00a0Spain to address cardio oncology through the implementation of AI MyoStrain and thus\u00a0be able to assess early the cardiac function of cancer patients and the cardiotoxicity of\u00a0the chemotherapy treatments.<\/p><p>This is a pioneering initiative in tracking and monitoring cardio-oncology patients based\u00a0on the Myostrain program, which directly and non-invasively evaluates the state of the\u00a0heart through a quick MRI in which no intravenous contrast or ionizing radiation is\u00a0used. Thanks to a program based on AI Myostrain, it is able to provide accurate, rapid\u00a0and early information on cardiac function and of any deformity of myocardial fibers to\u00a0detect early cardiac dysfunction to begin cardio-protective treatments and thereby open\u00a0the window of opportunity that prevents and reduces the incidence of heart failure in\u00a0cardio oncology patients.<\/p><p>This early detection and analysis tool is of special interest when analyzing the cardiac\u00a0health status of cancer patients, since it can provide early information on collateral damage to the heart and compare the state of the heart before and after any chemotherapy\u00a0or radiotherapy therapy. In the same way, carrying out the test during the period of time\u00a0in which chemotherapy is being applied, or after it, will provide a complete report on\u00a0the state of health of the myocardial tissue. This information will help healthcare professionals assess the suitability and success of certain treatments and ensure greater safety and comfort for patients.<\/p><p>\u201cHaving Myostrain technology gives us the possibility of detecting the possible cardiac\u00a0toxicity of some oncological treatments much earlier than we could do with the most\u00a0common diagnostic scans such as echocardiography. In short, it is a very important development to be able to offer optimal care to each of our patients, who are recipients of\u00a0both conventional oncological treatments and other treatments within the design of a\u00a0clinical trial with novel therapies,&#8221; says Dr. Antonio Cubillo, director of the Clara\u00a0Campal HM CIOCC Comprehensive Oncology Center.<\/p><p>\u201cIt is a real honour to support what will undoubtedly be a leading Cardio Oncology\u00a0program at HM Hospitales in Madrid. The implementation of the Myostrain technology\u00a0at the Sanchinarro University Hospital as the first in the system will open a new stage of\u00a0research and medical care for oncologists and cardiologists and will bring not only efficiency to the diagnosis, but will support the standardization of protocols for early detection of cardiovascular diseases,\u201d comented Dr. Rafael O. Rivero, CMO of Myocardial\u00a0Solutions.<\/p><p>On the other side, Dr. Leticia Fern\u00e1ndez Friera, director of the HM CIEC Comprehensive Center for Cardiovascular Diseases, points out \u201cthe importance of incorporating\u00a0tools into our diagnostic arsenal that help us be more precise in detecting early secondary cardiac cardiotoxicity to oncological treatments and even prevent unwanted damage to the myocardial tissue, in order to improve the survival of our oncological patients.&#8221;<\/p><p><strong>Synergy between disciplines\u00a0<\/strong><\/p><p>In fact, the application of this test is part of a greater development program within the\u00a0Group. This is one of the first actions that represent HM Hospitales&#8217; commitment to address Oncology and Cardiology in a multidisciplinary manner, two of the areas of maximum interest and specialization thanks to HM CIEC and HM CIOCC.<\/p><p>In this way, Myostrain represents one of the key pillars for the cardiac health of our oncology patients, but it is not limited only to this type of patient, but is also extensible to\u00a0those with cardiovascular problems, hypertensive patients, diabetics, valvular patients\u00a0or those with heart failure, etc., where we want to anticipate the deterioration of cardiac\u00a0function evaluated with other standard techniques, such as echocardiography.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\u2022 HM Sanchinarro, through HM CIEC and HM CIOCC, becomes the first private\u00a0hospital in Spain to address cardio oncology through the implementation of the\u00a0MyoStrain AI program. \u2022 This is one of the first actions that represent HM Hospitales&#8217; commitment to address Cardiology and Oncology in a multidisciplinary manner, two of the areas of\u00a0greatest interest and [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":3107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3106","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-category-1"],"_links":{"self":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts\/3106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/comments?post=3106"}],"version-history":[{"count":7,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts\/3106\/revisions"}],"predecessor-version":[{"id":3313,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts\/3106\/revisions\/3313"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/media\/3107"}],"wp:attachment":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/media?parent=3106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/categories?post=3106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/tags?post=3106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}